Panbela Therapeutics Inc. (PBLA)
(Delayed Data from OTC)
$0.40 USD
+0.02 (4.69%)
Updated Jun 7, 2024 03:38 PM ET
4-Sell of 5 4
F Value D Growth D Momentum F VGM
Brokerage Reports
Panbela Therapeutics Inc. [PBLA]
Reports for Purchase
Showing records 1 - 20 ( 74 total )
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2023 Results; Awaiting Data Readouts to Assure Path Forward; Target Adjusted Downward to $5
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Valuation Does Not Reflect Near-Term Potential Broad Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology and Medical Device Conference Note
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Optimism for Phase 3 SBP-101 Trial Upon NALIPIFOX 1st-Line mPDAC Approval
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ASPIRE 50% Enrolled, Recent DFMO Data Published, Cash Position Fortified
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FDA Approves US WorldMeds'' Eflornithine NDA in Pediatric Neuroblastoma
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
FDA Approval of Eflornithine in Neuroblastoma Validates Panbela''s Pipeline and Boosts Cash Reserves
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Published Abstract Shows SBP-101 DFMO In-Vitro Inhibition of MM Cells
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ASPIRE Passes Second DSMB Safety Review, Trial to Continue As Planned
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 ASPIRE Gets Second Green Light; Interim Analysis Expected in Early 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Valuation Does Not Reflect Near Term Potential Broad Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q23 Results; Clinical Pipeline Nears 2024 Data Readouts; Financial Overhang Looms
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Issued New E.U. Patent for Novel SBP-101 Production Process
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Pipeline Pushes Forward on All Fronts; ASPIRE Interim Analysis Expected Early 2024
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Panbela Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q23: Valuation Does Not Reflect Near Term Potential Broad Pipeline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J